GIIS109 – Inmunoterapias Celulares Avanzadas

Cecilia Pesini; Laura Artal; Jorge Paúl Bernal; Diego Sánchez-Martínez*; Julián Pardo; Ariel Ramírez-Labrada. 2024. In-depth analysis of the interplay between Oncogenic Mutations and NK Cell- Mediated Cancer Surveillance in Solid Tumors. Oncoimmunology. 13(1):2379062. https://doi.org/10.1080/2162402X.2024.2379062

Sofia Mensurado; Carolina Condeço; Diego Sánchez-Martínez; et al; Bruno Silva-Santos. 2024. CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells. Blood. pp. In press. 1st decile. (2024)

Anaïs Jimenez-Reinoso; Nestor Tirado; Alba Martínez-Moreno; et al; Diego Sánchez-Martínez*. 2022. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. Journal for Immunotherapy of Cancer. 10-12, pp.e005333. doi:10.1136/jitc-2022-005333. 1st quartile. (2022)

Diego Sánchez-Martínez*; Néstor Tirado; Sofia Mensurado; et al; Pablo Menendez. 2022. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia. Journal for Immunotherapy of Cancer. 10-9, pp.e005400. doi: 10.1136/jitc-2022-005400. 1st quartile. (2022)

Samanta Romina Zanetti; Talia Velasco-Hernandez; …; Diego Sanchez-Martinez; et al; Pablo Menendez;. 20. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy. 30. https://doi.org/10.1016/j.ymthe.2021.08.03. 1st quartile. (2021)

Diego Sánchez-Martínez*; Francisco Gutiérrez-Agüera;Paola Romecin; et al; Pablo Menéndez. 2021. Enforced sialyl-Lewis-X (sLeX) displayin E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activityand bone marrow homing. Clinical and Translational Medicine. 11-2, pp.e280. doi:10.1002/ctm2.280. 1st quartile. (2021)

Matteo L Baroni; Diego Sánchez-Martínez; Francisco Gutierrez-Agüera; et al; Pablo Menéndez. 2020. 4-1BB-based andCD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. Journal for Immunotherapy of Cancer. 8-1, pp.e000845. doi: 10.1136/jitc-2020-000845. 1st quartile. (2020)

Velasco-Hernandez T; Zanetti SR; Roca-Ho H; …; Sánchez-Martínez D ; et al; Menéndez P. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope. Journal for Immunotherapy of Cancer. 8-2. https://doi.org/10.1136/jitc2020-000896. 1st quartile. (2020)

Tania Calvo; Chantal Reina-Ortiz; David Giraldos; …; Diego Sánchez-Martínez; et al; Alberto Anel. Expanded and activated allogeneic NK cells are cytotoxic against B‑chronic lymphocytic leukemia (B‑CLL) cells with sporadic cases of resistance. Scientific Reports. 10-1, pp.19398. 1st quartile. (2020)

Clara Bueno; Talia Velasco; Francisco Gutierrez-Agüera; …; Diego Sanchez-Martinez; et al; Pablo Menendez; CD133-directed CART cells for MLL B-cell ALL: on target, off-tumor myeloablative toxicity. Leukemia. 33-8, pp.2090-2125. 1st decile. (2019)

Diego Sánchez-Martínez*; Matteo L Baroni; Francisco Gutierrez-Agüera; et al; Pablo Menendez. 2019. Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 133-21, pp.2291-2304. https://doi.org/10.1182/blood-2018-10-882944. 1st decile. (2019)

Belen Lopez-Millan; Diego Sanchez-Martinez; Heleia Roca-Ho; et al; Pablo Menendez. 2019. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia. 33(7):1557-1569.. https://doi.org/10.1038/s41375-018-0353-0. 1st decile. (2019)